MiMedx' HydroFix Vaso Shield receives FDA clearance for additional thicknesses and sizes

NewsGuard 100/100 Score

MiMedx Group, Inc. (OTC Bulletin Board: MDXG), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification by the FDA that the Company's proprietary device, HydroFix™ Vaso Shield, has received 510(k) clearance for additional thicknesses and sizes.  

In April 2009, the FDA cleared HydroFix™ Vaso Shield for use as a cover for vessels following anterior vertebral surgeries. The Vaso Shield is a permanent and transparent hydrogel product protected by multiple patents and patent applications, as well as a proprietary manufacturing process. During an anterior spinal implant procedure, the physician places the Vaso Shield between the spinal implant site and the vessels and then sutures it to the perivertebral, non-vascular soft tissue to secure the implant. The device is designed to protect the vessels in subsequent anterior revision surgeries.

Parker H. "Pete" Petit, MiMedx Chairman and Chief Executive Officer, said, "In the initial 510(k) FDA submission, the device was presented with a thickness of 1.0mm. During the "soft launch" of HydroFix™ Vaso Shield, the physician receptivity was excellent and we received valuable feedback that they wanted to utilize the device in varying thicknesses. In response to their feedback, we submitted a subsequent 510(k) for the device. The FDA has now cleared HydroFix™ Vaso Shield for multiple thicknesses ranging from 0.4mm to 1.0mm and multiple sizes."

"We are excited about the opportunity to expand the marketing of our product with the multiple thickness clearance and further serve the needs and surgical preferences of the physicians that utilize our devices," added Petit.

The Company will also expand its European product offering of HydroFix™ Spine Shield to offer similar configurations as the HydroFix™ Vaso Shield.

MiMedx also reported that it has recently completed a Level 2 Comprehensive FDA Inspection of its Marietta, Georgia facility and was pleased with the results.  William C. Taylor, MiMedx President and Chief Operating Officer, commented, "It is a very difficult job to establish a strong, compliant quality system in a start-up organization and it is even more difficult to ensure compliance with that system.  We are very proud of our team. The results of the audit prove that our team has done a great job, and demonstrate management's commitment to producing high quality products that meet or exceed applicable regulatory requirements."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.